BRIEF published on 01/29/2025 at 08:05, 1 year 7 months ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
BRIEF published on 01/29/2025 at 08:05, 1 year 7 months ago TME Pharma et aimed analytics : Partenariat innovant pour la découverte de médicaments par l'IA Biotechnologie Partenariat Intelligence Artificielle Cancer Médicaments
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 7 months ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year 7 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une collaboration avec aimed analytics pour optimiser la découverte de médicaments par IA, renforçant son profil stratégique Collaboration IA Médicaments TME Pharma Aimed Analytics
BRIEF published on 12/23/2024 at 21:09, 1 year 8 months ago Successful public offering of TME Pharma NV Shareholders Capital Increase Cancer Financial Strategies NOX-A12
BRIEF published on 12/23/2024 at 21:09, 1 year 8 months ago Succès de l'offre publique de TME Pharma N.V. Actionnaires Augmentation De Capital Cancer NOX-A12 Stratégies Financières
PRESS RELEASE published on 12/23/2024 at 21:04, 1 year 8 months ago Informations privilégiées / Autres communiqués TME Pharma réussit son offre publique de 2,6 millions d'euros, renforçant sa position financière jusqu'en juin 2025. Les actionnaires soutiennent la levée de fonds pour NOX-A12 et NOX-E36 Augmentation De Capital Offre Publique TME Pharma NOX-A12 NOX-E36
BRIEF published on 12/04/2024 at 19:55, 1 year 9 months ago TME Pharma annonce une mise à jour stratégique et un plan de financement de 2,6 millions d'euros Stratégie D'entreprise Offre Publique Plan De Financement Développement Du NOX-A12 Priorité Aux Actionnaires
BRIEF published on 12/04/2024 at 19:55, 1 year 9 months ago TME Pharma Announces Strategic Update and €2.6 Million Financing Plan Public Offer Corporate Strategy Financing Plan NOX-A12 Development Shareholder Priority
PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 9 months ago Informations privilégiées / Autres communiqués TME Pharma annonce une nouvelle stratégie et un financement garanti de 2,6 millions d'euros pour ses projets NOX-A12 et NOX-E36 jusqu'en juin 2025 Financement Offre Publique TME Pharma NOX-A12 NOX-E36
Published on 09/12/2026 at 02:35, 14 hours 4 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 17 hours 39 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 18 hours 34 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 19 hours 14 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 23 hours 39 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 9 hours 8 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 18 hours 24 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 18 hours 28 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 20 hours 54 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 22 hours 23 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 21 hours ago Availability of the 2026 Interim Financial Report
